Study shows COVID patients are prone to developing anxiety and depression
FacebookTwitterEmail
Nearly one-fourth of patients develop anxiety, a mood disorder such as depression or a psychotic condition six months after having COVID-19, among a number of long-lasting aftereffects of the disease, according to a new study reported in The Lancet medical journal.
Substance use disorder and insomnia also were reported in some patients, as well as bleeding in the brain and strokes.
However, factors not directly related to the infection itself, such as isolation from family and friends, job loss and a death in the family, as well as health conditions such as obesity, diabetes and high blood pressure, also play a role in neurological diseases, according to Dr. Sharon Stoll, a neurologist with Yale Medicine who specializes in the study of the immune system.
Sharon Stoll, DO, MS
Dr. Sharon Stoll is a board certified neurologist, she is a multiple sclerosis specialist and assistant professor, in the department of neurology at Yale School of Medicine. She completed her neurology residency training at Thomas Jefferson University Hospital in Philadelphia, PA and her Neuroimmunology fellowship at Yale New Haven Hospital. Dr. Stoll continues to play an active role in academic development and continuing medical education and serves as the course director for Yale’s annual MS CME program. She is an investigator on several international multi-center clinical trials and currently serves on several advisory boards including BeCare MS Link, Forepont Capital Partners, One Touch Telehealth and JOWMA. Dr. Stoll has received numerous awards including the Rodney Bell teaching award and is a national multiple sclerosis society clinical fellowship grant recipient. Dr. Stoll also spent time as a medical editor at ABC news headquarters and is currently me